Immediate and Midterm Efficacy and Safety of Intravascular Lithotripsy for Calcified In‐Stent Restenosis: A Systematic Review and Meta‐Analysis

Fuente: Wiley Open Access
Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rifqi Rizkani Eri, Sania Zahrani, Prasetyo Andriono, Todung D. A. Silalahi
Format: Artículo Open Access
Publié: Wiley 2025
Sujets:
Accès en ligne:
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1867021818595901440
author Rifqi Rizkani Eri
Sania Zahrani
Prasetyo Andriono
Todung D. A. Silalahi
author_facet Rifqi Rizkani Eri
Sania Zahrani
Prasetyo Andriono
Todung D. A. Silalahi
Rifqi Rizkani Eri
Sania Zahrani
Prasetyo Andriono
Todung D. A. Silalahi
collection Wiley Open Access
contents Immediate and Midterm Efficacy and Safety of Intravascular Lithotripsy for Calcified In‐Stent Restenosis: A Systematic Review and Meta‐Analysis Rifqi Rizkani Eri Sania Zahrani Prasetyo Andriono Todung D. A. Silalahi Catheterization and Cardiovascular Interventions ABSTRACT Background In‐stent restenosis (ISR) remains a major challenge in coronary revascularization, especially in lesions with heavy calcification, where recurrence rates are high. The lack of data on newer treatment options often creates dilemmas for both physicians and patients. Intravascular lithotripsy (IVL) is a relatively new technique that has shown promise in managing calcified ISR. This meta‐analysis aims to evaluate the procedural success and clinical outcomes of IVL in this setting. Methods Following PRISMA 2020 guidelines, a systematic search was conducted on PubMed, ScienceDirect, and SCOPUS. Studies reporting procedural success and major adverse cardiovascular events (MACE) of IVL for calcified ISR during follow‐up were included. The Newcastle‐Ottawa Scale was used to assess study quality. Data analysis was performed using RevMan 5.4.0 and SPSS v25. Results Five studies with a total of 207 patients and 212 lesions treated were analyzed. Acute procedural success was 85% (95% CI 0.76–0.91, I ² = 42.0%). At 1‐year follow‐up, major adverse cardiac events (MACE) included myocardial infarction (MI) in 6% of patients (95% CI 0.02–0.16, I ² = 52.5%), target lesion revascularization in 13% (95% CI 0.08–0.20, I ² = 45.8%), and cardiac death in 4% (95% CI 0.02–0.08, I ² = 0.0%). The rate of periprocedural MI was 1.5% (95% CI 0.01‐0.05, I 2  = 0.0%), while no reflow phenomenon was 0.5% (95% CI 0.01‐0.06, I 2  = 0.0%), with no other procedural complication occured. The overall incidence of MACE was 16% (95% CI 0.07–0.33, I ² = 69.8%). Conclusion IVL shows potential as a treatment option for for calcified‐ISR, demonstrating high acute procedural success and acceptable 1‐year clinical outcomes. The 1‐year TLR (13%) and MACE (16%) rates compare favorably with historical data for non‐IVL strategies. Further large‐scale, controlled studies with longer follow‐up are needed to further validate its long‐term safety and effectiveness. 10.1002/ccd.70296 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ccd.70296
format Artículo Open Access
id wiley_oa_10_1002_ccd_70296
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Immediate and Midterm Efficacy and Safety of Intravascular Lithotripsy for Calcified In‐Stent Restenosis: A Systematic Review and Meta‐Analysis
Rifqi Rizkani Eri
Sania Zahrani
Prasetyo Andriono
Todung D. A. Silalahi
Catheterization and Cardiovascular Interventions
Immediate and Midterm Efficacy and Safety of Intravascular Lithotripsy for Calcified In‐Stent Restenosis: A Systematic Review and Meta‐Analysis Rifqi Rizkani Eri Sania Zahrani Prasetyo Andriono Todung D. A. Silalahi Catheterization and Cardiovascular Interventions ABSTRACT Background In‐stent restenosis (ISR) remains a major challenge in coronary revascularization, especially in lesions with heavy calcification, where recurrence rates are high. The lack of data on newer treatment options often creates dilemmas for both physicians and patients. Intravascular lithotripsy (IVL) is a relatively new technique that has shown promise in managing calcified ISR. This meta‐analysis aims to evaluate the procedural success and clinical outcomes of IVL in this setting. Methods Following PRISMA 2020 guidelines, a systematic search was conducted on PubMed, ScienceDirect, and SCOPUS. Studies reporting procedural success and major adverse cardiovascular events (MACE) of IVL for calcified ISR during follow‐up were included. The Newcastle‐Ottawa Scale was used to assess study quality. Data analysis was performed using RevMan 5.4.0 and SPSS v25. Results Five studies with a total of 207 patients and 212 lesions treated were analyzed. Acute procedural success was 85% (95% CI 0.76–0.91, I ² = 42.0%). At 1‐year follow‐up, major adverse cardiac events (MACE) included myocardial infarction (MI) in 6% of patients (95% CI 0.02–0.16, I ² = 52.5%), target lesion revascularization in 13% (95% CI 0.08–0.20, I ² = 45.8%), and cardiac death in 4% (95% CI 0.02–0.08, I ² = 0.0%). The rate of periprocedural MI was 1.5% (95% CI 0.01‐0.05, I 2  = 0.0%), while no reflow phenomenon was 0.5% (95% CI 0.01‐0.06, I 2  = 0.0%), with no other procedural complication occured. The overall incidence of MACE was 16% (95% CI 0.07–0.33, I ² = 69.8%). Conclusion IVL shows potential as a treatment option for for calcified‐ISR, demonstrating high acute procedural success and acceptable 1‐year clinical outcomes. The 1‐year TLR (13%) and MACE (16%) rates compare favorably with historical data for non‐IVL strategies. Further large‐scale, controlled studies with longer follow‐up are needed to further validate its long‐term safety and effectiveness. 10.1002/ccd.70296 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Immediate and Midterm Efficacy and Safety of Intravascular Lithotripsy for Calcified In‐Stent Restenosis: A Systematic Review and Meta‐Analysis
topic Catheterization and Cardiovascular Interventions
url https://onlinelibrary.wiley.com/doi/10.1002/ccd.70296